osteoclastic

Cyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε. Cyt-PTPε Inhibitor-1 blocks the dephosphorylation of c-Src and exhibits anti-osteoclastic activity.

Clodronic acid disodium salt (Lodronate), a bisphosphonate, is a potent antiosteolytic agent which inhibits bone resorption.

3-(3-Hydroxyphenyl)propionic Acid (m-Hydroxyphenylpropionic acid) is one of the major metabolites of ingested caffeic acid.it inhibited osteoclastogenesis and bone osteoclastic resorptive activity.

ABD-295 is an antiresorptive agent, osteoclast inhibitor, and biphenylsulfide derivative. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo.

Deoxypyridinoline is one of two pyridinium cross-links that provide structural stiffness to type I collagen found in bones. It is excreted unmetabolized in urine and is a specific marker of bone resorption and osteoclastic activity.

PKC fragment (530-558) is a peptide fragment of protein kinase C (PKC) and is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption.

Rubiadin-1-methyl ether (Rubiadin 1-methyl ether) is a natural product.It inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65.

NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].

NS-3736 is a chloride channel inhibitor that has been shown to prevent osteoclastic acidification and resorption.

Osteoprotegerin is a soluble secreted member of the tumor necrosis factor receptor superfamily, inhibiting osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, leading to excess accumulation of bone and cartilage.

Osteostatin, derived from parathyroid hormone-related protein (PTHrP) 107-111, has demonstrated properties conducive to bone repair in animal models presenting with bone defects and exhibits efficacy in mitigating bone erosion associated with inflammatory arthritis. Additionally, it possesses the capacity to inhibit both collagen-induced arthritis and direct osteoclastic bone resorption, marking its potential utility in inflammation and immunology research [1] [2] [3] [4].

Curculigoside B shows antioxidative and antiosteoporotic activities, it can decrease area of bone resorption pit, osteoclastic formation and TRAP activity.

Matairesinol is a phytolignan found in a variety of foods such as seeds, vegetables and fruits.Matairesinol has a variety of biological functions including anti-angiogenic, anti-cancer and anti-fungal activities; the anti-osteoporotic activity of matairesinol may derive from its anti-osteoclastic potential through p38 ERK-NFATc1 signaling , rather than through an anti-resorptive effect.

3'4'7-Trihydroxyflavone can markedly inhibit the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastic differentiation from mouse bone marrow derived macrophages (BMMs), it inhibits osteoclastogenesis via nuclear factor of activ

Dalbergiphenol shows antiosteoporotic activity, dalbergiphenol treatment can effectively prevent OVX-induced increase in bone loss and decrease in bone strength possibly by increasing osteoblastic activities and by decreasing osteoclastic activities.

Calcitonin, porcine, inhibits 1,25 (OH) 2 D 3-stimulated porcine osteoclast differentiation. As a polypeptide hormone, Calcitonin can lower serum calcium by decreasing calcium reabsorption in the kidney and inhibiting osteoclastic bone resorption. Calcitonin, porcine, can be used for research of hypercalcemia [1] [2].